Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is a genomic diagnostics company that provides tests for various types of cancer, including prostate, thyroid, breast, and bladder. They have a positive outlook due to potential market growth, successful clinical data for their breast cancer test Prosigna, and plans for international expansion. The company has also exceeded financial expectations and has a strong development pipeline, but there are potential risks to consider.

Bears say

Veracyte is a genomic diagnostics company with a portfolio of tests for prostate, thyroid, breast, and bladder cancers. While the company has shown strong revenue growth in recent years and has potential for continued success with new partnerships, there are concerns about the sustainability of this growth and the company's margin performance. Additionally, its dependency on a small portion of its revenue from the Prosigna test and potential competition in the future could impact its financials.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.